Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
07 juin 2023 07h30 HE
|
Entera Bio Ltd.
JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
18 avr. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
18 avr. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by SanofiMechanism of Action of Tiziana’s first-in-class, only...
Middle East and Africa Human Insulin Market is anticipated to register a CAGR of greater than 4% during 2023 – 2028 - Market Size, Share, Forecasts, and Trends Analysis Report by Mordor Intelligence.
05 avr. 2023 09h00 HE
|
Mordor Intelligence
Hyderabad, April 05, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Middle East and Africa Human Insulin Market - (2023 – 2028),” the market is expected to register a...
SHAREHOLDER ALERT: Morris Kandinov Investigating PRVB, MAXR, DNA, and FOX; Shareholders are Encouraged to Contact the Firm
29 mars 2023 09h00 HE
|
Morris Kandinov, LLP
SAN DIEGO, March 29, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating Provention Bio, Inc., Maxar Technologies Inc., Ginkgo Bioworks Holdings, Inc., and Fox Corporation....
Sanofi, market leader in DTaP pediatric combination vaccines, with 55.4 million doses used in 2021
23 févr. 2023 14h00 HE
|
ReportLinker
Lyon, France, Feb. 23, 2023 (GLOBE NEWSWIRE) -- A new study shows that Sanofi is the global market leader among aP-based pediatric combination vaccines with a 74.7% share, leading the move from...
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
07 déc. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
08 nov. 2022 09h00 HE
|
InSilico Medicine
Abu Dhabi, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research...
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
08 nov. 2022 09h00 HE
|
InSilico Medicine
New York, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research...
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
09 août 2022 16h02 HE
|
Revolution Medicines, Inc.
First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers ...